Summary & Overview
Permanent Cardiac Pacemaker Implant with MCC: Inpatient Reimbursement Overview
DRG 242 addresses inpatient stays for permanent cardiac pacemaker implantation with a Major Complication or Comorbidity, encompassing cases with elevated clinical complexity. This classification matters for inpatient reimbursement because the Major Complication or Comorbidity status increases expected resource use and typically results in higher Medicare payment than similar cases without such comorbidity.
DRG 242 Overview
DRG 242 covers inpatient admissions for permanent cardiac pacemaker implantations when a Major Complication or Comorbidity is present. This includes procedures for inserting or replacing permanent pacemaker systems in patients with significant additional diagnoses that increase clinical complexity. The presence of a Major Complication or Comorbidity elevates resource use and impacts Medicare inpatient reimbursement. Accurate coding of the pacemaker procedure and accompanying major conditions determines payment assignment under the Diagnosis-Related Group system.
Clinical Trials
- Acute procedural optimization studies assessing different lead placement techniques, pacing modes, or implant approaches in patients undergoing initial permanent pacemaker implantation for symptomatic bradyarrhythmias or atrioventricular block. These trials enroll hospitalized adults who meet guideline criteria for device implantation and compare immediate periprocedural outcomes such as procedure duration, lead stability, acute complications (e.g., pneumothorax, hematoma), and in-hospital length of stay. Findings inform clinicians on safest, most efficient implant strategies and help payers anticipate resource utilization and complication-related costs for this high-acuity DRG.
- Comparative effectiveness and device programming trials that evaluate single- versus dual-chamber pacemakers, different rate-response algorithms, or battery/lead technologies in patients with chronic conduction disease or sick sinus syndrome. These studies typically include both inpatient implants and short-term follow-up to measure symptom control, need for reintervention, infection rates, and medium-term readmissions. Results are relevant for guiding device selection, coding and reimbursement decisions, and predicting downstream costs associated with device longevity and complication profiles.
- Post-discharge registry and outcomes research focused on long-term complications, infection surveillance, and readmission prevention in patients after permanent pacemaker implantation, including bundles for early follow-up, wound care protocols, and remote monitoring effectiveness. These observational cohorts capture real-world populations across ages and comorbidity burdens to quantify rates of device infection, lead malfunction, and unplanned rehospitalization within 30–90 days and beyond. Data support quality improvement initiatives, value-based payment models, and payer strategies to reduce preventable readmissions and manage chronic device-related costs.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.